D J Harman1, S D Ryder1, M W James1, E A Wilkes1, T R Card1,2, G P Aithal1,3, I N Guha1,3. 1. National Institute for Health Research (NIHR) Nottingham Biomedical Research Centre (BRC), Nottingham University Hospitals NHS Trust, University Of Nottingham, Nottingham, UK. 2. Division of Epidemiology and Public Health, City Hospital Campus, University of Nottingham, Nottingham, UK. 3. Nottingham Digestive Diseases Centre, University of Nottingham, Nottingham, UK.
Abstract
BACKGROUND: Rising cirrhosis incidence and mortality in the United Kingdom has been attributed predominantly to excess alcohol consumption. However, metabolic risk factors such as Type 2 diabetes and obesity may also be important. AIM: To screen at-risk individuals in general practice for undetected cirrhosis using transient elastography and study the risk factors underlying these cases. METHODS: The study was undertaken in 4 general practices (adult patient population 20 868) between February 2012 and September 2014. Patients with defined risk factors for chronic liver disease (hazardous alcohol use and/or Type 2 diabetes) were identified from the General Practice electronic records and invited for transient elastography. Elevated liver stiffness was defined as ≥8 kPa. Cirrhosis was confirmed by established histological, radiological and biochemical methods. RESULTS: Two thousand three hundred and sixty eight patients were invited for transient elastography and 899/919 who attended (97.8%) had valid measurements. Of these 230 patients had elevated liver stiffness (25.6%) and 27 had cirrhosis (2.9%). Risk factors for new cirrhosis diagnoses were obesity and/or Type 2 diabetes in 16 patients (59.3%), alcohol alone in 3 (11.1%) and both alcohol and obesity and/or diabetes in eight (29.6%). Presence of cirrhosis was significantly increased in obese patients with Type 2 diabetes or hazardous alcohol use compared to non-obese (odds ratio 9.4 [95% CI 2.2-40.9] and 5.6 [95% CI 1.6-19.7] respectively). CONCLUSIONS: The number of new cases of cirrhosis diagnosed clearly demonstrates that existing estimates of prevalence are likely to be gross underestimates. Obesity was an important risk factor for cirrhosis within both alcohol users and diabetics.
BACKGROUND: Rising cirrhosis incidence and mortality in the United Kingdom has been attributed predominantly to excess alcohol consumption. However, metabolic risk factors such as Type 2 diabetes and obesity may also be important. AIM: To screen at-risk individuals in general practice for undetected cirrhosis using transient elastography and study the risk factors underlying these cases. METHODS: The study was undertaken in 4 general practices (adult patient population 20 868) between February 2012 and September 2014. Patients with defined risk factors for chronic liver disease (hazardous alcohol use and/or Type 2 diabetes) were identified from the General Practice electronic records and invited for transient elastography. Elevated liver stiffness was defined as ≥8 kPa. Cirrhosis was confirmed by established histological, radiological and biochemical methods. RESULTS: Two thousand three hundred and sixty eight patients were invited for transient elastography and 899/919 who attended (97.8%) had valid measurements. Of these 230 patients had elevated liver stiffness (25.6%) and 27 had cirrhosis (2.9%). Risk factors for new cirrhosis diagnoses were obesity and/or Type 2 diabetes in 16 patients (59.3%), alcohol alone in 3 (11.1%) and both alcohol and obesity and/or diabetes in eight (29.6%). Presence of cirrhosis was significantly increased in obese patients with Type 2 diabetes or hazardous alcohol use compared to non-obese (odds ratio 9.4 [95% CI 2.2-40.9] and 5.6 [95% CI 1.6-19.7] respectively). CONCLUSIONS: The number of new cases of cirrhosis diagnosed clearly demonstrates that existing estimates of prevalence are likely to be gross underestimates. Obesity was an important risk factor for cirrhosis within both alcohol users and diabetics.
Authors: Matias A Avila; Jean-François Dufour; Alexander L Gerbes; Fabien Zoulim; Ramon Bataller; Patrizia Burra; Helena Cortez-Pinto; Bin Gao; Ian Gilmore; Philippe Mathurin; Christophe Moreno; Vladimir Poznyak; Bernd Schnabl; Gyongyi Szabo; Maja Thiele; Mark R Thursz Journal: Gut Date: 2019-12-26 Impact factor: 23.059
Authors: Gordon P Watt; Isela De La Cerda; Jen-Jung Pan; Michael B Fallon; Laura Beretta; Rohit Loomba; Miryoung Lee; Joseph B McCormick; Susan P Fisher-Hoch Journal: Hepatol Commun Date: 2020-10-31
Authors: Mohsan Subhani; Katy A Jones; Kirsty Sprange; Stefan Rennick-Egglestone; Holly Knight; Joanne R Morling; Doyo G Enki; Andrew Wragg; Stephen D Ryder Journal: BMJ Open Date: 2021-11-03 Impact factor: 2.692
Authors: J Chalmers; E Wilkes; R Harris; L Kent; S Kinra; G P Aithal; M Holmes; J Johnson; J R Morling; I N Guha Journal: Frontline Gastroenterol Date: 2019-06-26
Authors: Valentin Blank; David Petroff; Sebastian Beer; Albrecht Böhlig; Maria Heni; Thomas Berg; Yvonne Bausback; Arne Dietrich; Anke Tönjes; Marcus Hollenbach; Matthias Blüher; Volker Keim; Johannes Wiegand; Thomas Karlas Journal: Sci Rep Date: 2020-10-27 Impact factor: 4.379
Authors: Ahmad Moolla; Jasper de Boer; David Pavlov; Amin Amin; Angela Taylor; Lorna Gilligan; Beverly Hughes; John Ryan; Eleanor Barnes; Zaki Hassan-Smith; Jane Grove; Guruprasad P Aithal; An Verrijken; Sven Francque; Luc Van Gaal; Matthew J Armstrong; Phillip N Newsome; Jeremy F Cobbold; Wiebke Arlt; Michael Biehl; Jeremy W Tomlinson Journal: Aliment Pharmacol Ther Date: 2020-04-16 Impact factor: 9.524